secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001824293-23-000172
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports Q3 net loss $11M; cash $3.5M; IPF trial on track
----------------------------------------------------------------

- Net loss $11.0M for 9 months ended Sep 30, 2023; R&D expenses $2.2M (vs $0.2M YoY) and G&A $7.2M (vs $0.4M YoY).
- Cash and equivalents $3.5M as of Sep 30, 2023.
- Phase 2a biomarker study of GRI-0621 for IPF on track to start before year-end 2023; interim data expected H1 2024.
- GRI-0803 SLE program on track for IND filing H1 2024; Phase 1a SAD topline data expected Q3 2024.
- Entered asset purchase agreement with Aardvark Therapeutics to sell legacy ADAIR assets and IP (no financial terms disclosed).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/0001824293-23-000172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/val-20231115.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer